Prospective multicenter study of the impact of Oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients

Oncologist

Volumn 19, Issue 5, 2014, Pages 492-497

  Srivastava, Geetika ^a   Renfro, Lindsay A ^a   Behrens, Robert J ^b   Lopatin, Margarita ^c   Chao, Calvin ^c   Soori, Gamini S ^d   Dakhil, Shaker R ^e   Mowat, Rex B ^f   Philip Kuebler, J ^g   Kim, George ^h   Mazurczak, Miroslaw ⁱ   Lee, Mark ^c   Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

^b Medical Oncology and Hematology Associates   (United States)

^c Genomic Health Inc   (United States)

^d Department of Cardiothoracic and Vascular Surgery   (United States)

^e Cancer CenterofKansas   (United States)

^f Toledo Clinic   (United States)

^g Department of Pharmacy   (United States)

^h MAYO CLINIC   (United States)

ⁱ Sanford Children's Hospital   (United States)

Author keywords

Adjuvant; Chemotherapy; Colon cancer; Decision analysis; Risk assessment

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TUMOR MARKER;

ADULT; AGED; ALGORITHM; ARTICLE; ASSAY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; COLON CANCER; FEMALE; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BIOASSAY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONIC NEOPLASMS; DECISION MAKING; DECISION SUPPORT SYSTEM; GENETICS; MIDDLE AGED; TUMOR RECURRENCE; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BIOLOGICAL ASSAY; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84900001219     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0401     Document Type: Article

References (16)

1. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
2. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
3. Sargent D, Sobrero A, Grothey A et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-877.
4. Gray RG, Quirke P, Handley K et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011;29:4611-4619.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines: Colon cancer. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed April 1, 2013.
6. Vicuna B, Benson AB III. Adjuvant therapy for stage II colon cancer: Prognostic and predictive markers. J Natl ComprCanc Netw 2007;5:927-936.
7. Petersen VC, Baxter KJ, Love SB et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002;51:65-69.
8. Morris EJ, Maughan NJ, Forman D et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007;56:1419-1425.
9. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349: 247-257.
10. O'Connell MJ, Lavery I, Yothers G et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-3944.
11. O'Connell M, Lee M, Lopatin M et al.Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU)and 5FU/LV+oxaliplatin (FU+Ox).J Clin Oncol 2012;30(suppl):3512a.
12. Venook AP, Niedzwiecki D, Lopatin M et al. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC)fromCALGB9581. J Clin Oncol 2011;29(suppl): 3518a.
13. Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22: 3408-3419.
14. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.
15. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010;28: 1829-1834.
16. Alberts SR, Yu T, Behrens RJ et al. Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer. J Clin Oncol 2012; 30(suppl 34):391a.